» Articles » PMID: 30022943

Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed As Lung Cancer

Overview
Journal Case Rep Oncol
Publisher Karger
Specialty Oncology
Date 2018 Jul 20
PMID 30022943
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations or other alterations in the gene have been implicated in a variety of malignancies - most commonly thyroid, but also chronic myelomonocytic leukemia, acute myeloid leukemia, and lung, breast, pancreatic, and colon cancers. Here we present a case of a gentlemen initially diagnosed with and treated for non-small cell lung adenocarcinoma. Genomic profiling of his tumor specimen revealed a point mutation with a known association with medullary thyroid cancer (MTC). Further pathological and molecular diagnostic evaluation confirmed a diagnosis of MTC, leading to a change in treatment from standard chemotherapy for non-small cell lung cancer to targeted therapy against RET and potential implications regarding inherited cancer risk for his offspring. The patient experienced a clinical response to treatment and several months of improved quality of life. This case illustrates the capacity of genomic profiling to uncover molecular drivers of disease and help ensure proper diagnosis and management of cancer.

Citing Articles

Analysis of the lower incidence of medullary thyroid cancer in China.

Huang M, Fanciulli G, Wu S, Zhang Z, Zhang J Chin Med J (Engl). 2019; 132(20):2516-2517.

PMID: 31634241 PMC: 6831069. DOI: 10.1097/CM9.0000000000000463.

References
1.
Bos M, Gardizi M, Schildhaus H, Buettner R, Wolf J . Activated RET and ROS: two new driver mutations in lung adenocarcinoma. Transl Lung Cancer Res. 2015; 2(2):112-21. PMC: 4369857. DOI: 10.3978/j.issn.2218-6751.2013.03.08. View

2.
diSibio G, French S . Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008; 132(6):931-9. DOI: 10.5858/2008-132-931-MPOCRF. View

3.
Mu W, Lu H, Chen J, Li S, Elliott A . Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing. J Mol Diagn. 2016; 18(6):923-932. DOI: 10.1016/j.jmoldx.2016.07.006. View

4.
Mulligan L . RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014; 14(3):173-86. DOI: 10.1038/nrc3680. View

5.
Wey S, Chang K . Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms. Case Rep Pathol. 2015; 2015:153932. PMC: 4313001. DOI: 10.1155/2015/153932. View